The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes

Two neutralizing human mAbs, 2F5 and 4E10, that react with the HIV-1 envelope gp41 membrane proximal region are also polyspecific autoantibodies that bind to anionic phospholipids. To determine the autoantibody nature of these Abs, we have compared their reactivities with human anti-cardiolipin mAbs...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of Immunology Vol. 178; no. 7; pp. 4424 - 4435
Main Authors:	Alam, S Munir, McAdams, Mildred, Boren, David, Rak, Michael, Scearce, Richard M, Gao, Feng, Camacho, Zenaido T, Gewirth, Daniel, Kelsoe, Garnett, Chen, Pojen, Haynes, Barton F
Format:	Journal Article
Language:	English
Published:	England 01.04.2007
Subjects:	Amino Acid Sequence Animals Antibodies, Monoclonal - chemistry Antibodies, Monoclonal - immunology Antibody Specificity Antiphospholipid Syndrome - immunology Autoantibodies - immunology Cardiolipins - immunology HIV Antibodies - immunology HIV Envelope Protein gp41 - immunology HIV-1 - immunology Human immunodeficiency virus 1 Humans Lipids - immunology Liposomes - chemistry Mice Molecular Sequence Data
ISSN:	0022-1767, 1365-2567
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Two neutralizing human mAbs, 2F5 and 4E10, that react with the HIV-1 envelope gp41 membrane proximal region are also polyspecific autoantibodies that bind to anionic phospholipids. To determine the autoantibody nature of these Abs, we have compared their reactivities with human anti-cardiolipin mAbs derived from a primary antiphospholipid syndrome patient. To define the role of lipid polyreactivity in binding of 2F5 and 4E10 mAbs to HIV-1 envelope membrane proximal epitopes, we determined the kinetics of binding of mAbs 2F5 and 4E10 to their nominal gp41 epitopes vs liposome-gp41 peptide conjugates. Both anti-HIV-1 mAbs 2F5 and 4E10 bound to cardiolipin with K(d) values similar to those of autoimmune anti-cardiolipin Abs, IS4 and IS6. Binding kinetics studies revealed that mAb 2F5 and 4E10 binding to their respective gp41 peptide-lipid conjugates could best be defined by a two-step (encounter-docking) conformational change model. In contrast, binding of 2F5 and 4E10 mAbs to linear peptide epitopes followed a simple Langmuir model. A mouse mAb, 13H11, that cross-blocks mAb 2F5 binding to the gp41 epitope did not cross-react with lipids nor did it neutralize HIV-1 viruses. Taken together, these data demonstrate the similarity of 2F5 and 4E10 mAbs to known anti-cardiolipin Abs and support the model that mAb 2F5 and 4E10 binding to HIV-1 involves both viral lipid membrane and gp41 membrane proximal epitopes.
AbstractList	Two neutralizing human mAbs, 2F5 and 4E10, that react with the HIV-1 envelope gp41 membrane proximal region are also polyspecific autoantibodies that bind to anionic phospholipids. To determine the autoantibody nature of these Abs, we have compared their reactivities with human anti-cardiolipin mAbs derived from a primary antiphospholipid syndrome patient. To define the role of lipid polyreactivity in binding of 2F5 and 4E10 mAbs to HIV-1 envelope membrane proximal epitopes, we determined the kinetics of binding of mAbs 2F5 and 4E10 to their nominal gp41 epitopes vs liposome-gp41 peptide conjugates. Both anti-HIV-1 mAbs 2F5 and 4E10 bound to cardiolipin with K(d) values similar to those of autoimmune anti-cardiolipin Abs, IS4 and IS6. Binding kinetics studies revealed that mAb 2F5 and 4E10 binding to their respective gp41 peptide-lipid conjugates could best be defined by a two-step (encounter-docking) conformational change model. In contrast, binding of 2F5 and 4E10 mAbs to linear peptide epitopes followed a simple Langmuir model. A mouse mAb, 13H11, that cross-blocks mAb 2F5 binding to the gp41 epitope did not cross-react with lipids nor did it neutralize HIV-1 viruses. Taken together, these data demonstrate the similarity of 2F5 and 4E10 mAbs to known anti-cardiolipin Abs and support the model that mAb 2F5 and 4E10 binding to HIV-1 involves both viral lipid membrane and gp41 membrane proximal epitopes.Two neutralizing human mAbs, 2F5 and 4E10, that react with the HIV-1 envelope gp41 membrane proximal region are also polyspecific autoantibodies that bind to anionic phospholipids. To determine the autoantibody nature of these Abs, we have compared their reactivities with human anti-cardiolipin mAbs derived from a primary antiphospholipid syndrome patient. To define the role of lipid polyreactivity in binding of 2F5 and 4E10 mAbs to HIV-1 envelope membrane proximal epitopes, we determined the kinetics of binding of mAbs 2F5 and 4E10 to their nominal gp41 epitopes vs liposome-gp41 peptide conjugates. Both anti-HIV-1 mAbs 2F5 and 4E10 bound to cardiolipin with K(d) values similar to those of autoimmune anti-cardiolipin Abs, IS4 and IS6. Binding kinetics studies revealed that mAb 2F5 and 4E10 binding to their respective gp41 peptide-lipid conjugates could best be defined by a two-step (encounter-docking) conformational change model. In contrast, binding of 2F5 and 4E10 mAbs to linear peptide epitopes followed a simple Langmuir model. A mouse mAb, 13H11, that cross-blocks mAb 2F5 binding to the gp41 epitope did not cross-react with lipids nor did it neutralize HIV-1 viruses. Taken together, these data demonstrate the similarity of 2F5 and 4E10 mAbs to known anti-cardiolipin Abs and support the model that mAb 2F5 and 4E10 binding to HIV-1 involves both viral lipid membrane and gp41 membrane proximal epitopes. Two neutralizing human mAbs, 2F5 and 4E10, that react with the HIV-1 envelope gp41 membrane proximal region are also polyspecific autoantibodies that bind to anionic phospholipids. To determine the autoantibody nature of these Abs, we have compared their reactivities with human anti-cardiolipin mAbs derived from a primary antiphospholipid syndrome patient. To define the role of lipid polyreactivity in binding of 2F5 and 4E10 mAbs to HIV-1 envelope membrane proximal epitopes, we determined the kinetics of binding of mAbs 2F5 and 4E10 to their nominal gp41 epitopes vs liposome-gp41 peptide conjugates. Both anti-HIV-1 mAbs 2F5 and 4E10 bound to cardiolipin with K sub(d) values similar to those of autoimmune anti-cardiolipin Abs, IS4 and IS6. Binding kinetics studies revealed that mAb 2F5 and 4E10 binding to their respective gp41 peptide-lipid conjugates could best be defined by a two-step (encounter-docking) conformational change model. In contrast, binding of 2F5 and 4E10 mAbs to linear peptide epitopes followed a simple Langmuir model. A mouse mAb, 13H11, that cross-blocks mAb 2F5 binding to the gp41 epitope did not cross-react with lipids nor did it neutralize HIV-1 viruses. Taken together, these data demonstrate the similarity of 2F5 and 4E10 mAbs to known anti-cardiolipin Abs and support the model that mAb 2F5 and 4E10 binding to HIV-1 involves both viral lipid membrane and gp41 membrane proximal epitopes. Two neutralizing human mAbs, 2F5 and 4E10, that react with the HIV-1 envelope gp41 membrane proximal region are also polyspecific autoantibodies that bind to anionic phospholipids. To determine the autoantibody nature of these Abs, we have compared their reactivities with human anti-cardiolipin mAbs derived from a primary antiphospholipid syndrome patient. To define the role of lipid polyreactivity in binding of 2F5 and 4E10 mAbs to HIV-1 envelope membrane proximal epitopes, we determined the kinetics of binding of mAbs 2F5 and 4E10 to their nominal gp41 epitopes vs liposome-gp41 peptide conjugates. Both anti-HIV-1 mAbs 2F5 and 4E10 bound to cardiolipin with K(d) values similar to those of autoimmune anti-cardiolipin Abs, IS4 and IS6. Binding kinetics studies revealed that mAb 2F5 and 4E10 binding to their respective gp41 peptide-lipid conjugates could best be defined by a two-step (encounter-docking) conformational change model. In contrast, binding of 2F5 and 4E10 mAbs to linear peptide epitopes followed a simple Langmuir model. A mouse mAb, 13H11, that cross-blocks mAb 2F5 binding to the gp41 epitope did not cross-react with lipids nor did it neutralize HIV-1 viruses. Taken together, these data demonstrate the similarity of 2F5 and 4E10 mAbs to known anti-cardiolipin Abs and support the model that mAb 2F5 and 4E10 binding to HIV-1 involves both viral lipid membrane and gp41 membrane proximal epitopes.
Author	Camacho, Zenaido T Gewirth, Daniel Haynes, Barton F Boren, David Alam, S Munir McAdams, Mildred Kelsoe, Garnett Chen, Pojen Scearce, Richard M Gao, Feng Rak, Michael
Author_xml	– sequence: 1 givenname: S Munir surname: Alam fullname: Alam, S Munir email: alam0004@mc.duke.edu organization: Department of Medicine, Duke Human Vaccine Institute, Duke University School of Medicine, RP1 Circuit Drive, Durham, NC 27710, USA. alam0004@mc.duke.edu – sequence: 2 givenname: Mildred surname: McAdams fullname: McAdams, Mildred – sequence: 3 givenname: David surname: Boren fullname: Boren, David – sequence: 4 givenname: Michael surname: Rak fullname: Rak, Michael – sequence: 5 givenname: Richard M surname: Scearce fullname: Scearce, Richard M – sequence: 6 givenname: Feng surname: Gao fullname: Gao, Feng – sequence: 7 givenname: Zenaido T surname: Camacho fullname: Camacho, Zenaido T – sequence: 8 givenname: Daniel surname: Gewirth fullname: Gewirth, Daniel – sequence: 9 givenname: Garnett surname: Kelsoe fullname: Kelsoe, Garnett – sequence: 10 givenname: Pojen surname: Chen fullname: Chen, Pojen – sequence: 11 givenname: Barton F surname: Haynes fullname: Haynes, Barton F
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/17372000$$D View this record in MEDLINE/PubMed
BookMark	eNqFUU1v1DAQtVAR3RZ-ARLyiVsWe-zY2SOqWlqpUi-F68qOJ60rf4Q4qUh_JT8JL225ojmM5vnNe-OZE3KUckJCPnK2lUzuvjz4GJeUw5brbqu3UoJ8QzZcqLaBVukjsmEMoOFa6WNyUsoDY0wxkO_IMddCQy035PftPdIpB6R5oCbN3ma30jGHtYzY-8H3fl7rg6PBj97RCU0_-8cD6BO1Pjmf7g69dsrGhZUmXObJBP90wA-CzeXVj4ZTTI8Y8oj0fokm0ZhT7kNOJry6eiwULtq_XvKcMzpnehfWPo9TnrGaSU4jRjuZhLRiv3yszf9kcfRzzeU9eTuYUPDDSz4l3y_Ob88um-ubb1dnX6-bvhUwN61Q1g6COebsoLtOKiVh51ADGOE6trMtAqAAaeqqhFPdAIMZEGxvQQorTsnnZ906ys8Fy7yPvvQYQh0vL2Wvmaih9X-JfKeY1Aoq8dMLcbER3X6c6g-ndf96LPEHRUyegw
CitedBy_id	crossref_primary_10_1128_JVI_01604_09 crossref_primary_10_1371_journal_pone_0086905 crossref_primary_10_1016_j_coi_2017_06_004 crossref_primary_10_4049_jimmunol_1201303 crossref_primary_10_1089_aid_2010_0265 crossref_primary_10_1128_jvi_01647_22 crossref_primary_10_1002_cyto_a_20599 crossref_primary_10_1128_JVI_02257_09 crossref_primary_10_1073_pnas_1317855110 crossref_primary_10_1371_journal_ppat_1002200 crossref_primary_10_1016_j_it_2014_08_007 crossref_primary_10_1038_nsmb_2922 crossref_primary_10_1134_S0026893317060176 crossref_primary_10_1146_annurev_med_60_042507_164323 crossref_primary_10_1128_JVI_00846_08 crossref_primary_10_1073_pnas_1103869108 crossref_primary_10_3390_v12111210 crossref_primary_10_1128_JVI_00872_07 crossref_primary_10_1016_j_colsurfb_2017_01_032 crossref_primary_10_1128_JVI_02113_09 crossref_primary_10_1073_pnas_1307336110 crossref_primary_10_1093_infdis_jis183 crossref_primary_10_1097_COH_0b013e3282f9ae79 crossref_primary_10_1128_JVI_00033_08 crossref_primary_10_1371_journal_ppat_1003639 crossref_primary_10_1097_QAD_0b013e32834785cf crossref_primary_10_3390_vaccines9091001 crossref_primary_10_1186_1742_4690_10_3 crossref_primary_10_1038_s41467_018_07962_9 crossref_primary_10_1128_JVI_02363_09 crossref_primary_10_1016_j_vaccine_2009_05_059 crossref_primary_10_1038_nature12053 crossref_primary_10_3389_fimmu_2022_910367 crossref_primary_10_1016_j_virol_2008_02_007 crossref_primary_10_1038_nsmb0510_543 crossref_primary_10_1186_1742_4690_11_44 crossref_primary_10_1016_j_jmb_2008_09_024 crossref_primary_10_1128_JVI_01680_10 crossref_primary_10_1038_nri3516 crossref_primary_10_1128_JVI_02664_13 crossref_primary_10_1016_j_coviro_2019_02_004 crossref_primary_10_1128_JVI_02357_09 crossref_primary_10_1016_j_virol_2009_07_041 crossref_primary_10_1002_ange_201508421 crossref_primary_10_1073_pnas_0912381107 crossref_primary_10_1097_COH_0b013e32832edc50 crossref_primary_10_1097_QAD_0b013e3283292153 crossref_primary_10_1097_COH_0000000000000049 crossref_primary_10_1073_pnas_1120059109 crossref_primary_10_1089_aid_2008_0129 crossref_primary_10_1097_COH_0b013e32832f4a4d crossref_primary_10_1056_NEJMra066267 crossref_primary_10_1128_JVI_00571_09 crossref_primary_10_1371_journal_pone_0016857 crossref_primary_10_1089_vim_2019_0136 crossref_primary_10_1038_nri2674 crossref_primary_10_1016_j_febslet_2008_10_012 crossref_primary_10_1073_pnas_0909680107 crossref_primary_10_1074_jbc_M114_569566 crossref_primary_10_1097_QAD_0b013e328342ff11 crossref_primary_10_1016_j_immuni_2012_08_012 crossref_primary_10_1080_14760584_2019_1651649 crossref_primary_10_1016_j_jim_2013_11_026 crossref_primary_10_1007_s00018_011_0872_6 crossref_primary_10_1002_anie_201508421 crossref_primary_10_1128_JVI_05489_11 crossref_primary_10_1128_mSphere_00086_16 crossref_primary_10_1371_journal_pone_0024078 crossref_primary_10_1016_j_immuni_2007_11_018 crossref_primary_10_1016_j_immuni_2014_11_014 crossref_primary_10_1038_s41385_019_0164_2 crossref_primary_10_1016_j_bbamem_2008_11_015 crossref_primary_10_1128_JVI_00656_09 crossref_primary_10_1016_j_bbamem_2007_12_018 crossref_primary_10_1128_JVI_00718_12 crossref_primary_10_1016_j_febslet_2010_03_021 crossref_primary_10_1039_c2jm32016a crossref_primary_10_1128_jvi_00710_23 crossref_primary_10_1128_CVI_00615_12 crossref_primary_10_1016_j_chom_2019_09_016 crossref_primary_10_1128_JVI_03309_13 crossref_primary_10_1128_CVI_00425_10 crossref_primary_10_1016_j_cocis_2013_06_004 crossref_primary_10_1097_QAD_0b013e3283196a80 crossref_primary_10_1128_JVI_05045_11 crossref_primary_10_7554_eLife_90139 crossref_primary_10_1021_ja405990z crossref_primary_10_1159_000438484 crossref_primary_10_1016_j_sbi_2024_102897 crossref_primary_10_1038_nsmb_1944 crossref_primary_10_1038_gene_2012_16 crossref_primary_10_1097_COH_0000000000000820 crossref_primary_10_1371_journal_ppat_1006212 crossref_primary_10_1586_erv_10_52 crossref_primary_10_1097_COH_0000000000000148 crossref_primary_10_1371_journal_ppat_1002095 crossref_primary_10_1002_1873_3468_14814 crossref_primary_10_1016_j_immuni_2019_02_008 crossref_primary_10_1126_sciimmunol_aal2200 crossref_primary_10_1371_journal_pone_0025797 crossref_primary_10_4049_jimmunol_1900069 crossref_primary_10_1002_jgm_1277 crossref_primary_10_1016_j_cell_2014_06_022 crossref_primary_10_1371_journal_pone_0023532 crossref_primary_10_1016_j_jim_2011_10_005 crossref_primary_10_1074_jbc_M114_556266 crossref_primary_10_1093_infdis_jiaa377 crossref_primary_10_4049_jimmunol_2000732 crossref_primary_10_1126_scitranslmed_aaf0618 crossref_primary_10_1038_ni_1746 crossref_primary_10_1002_jia2_25831 crossref_primary_10_1128_JVI_06938_11 crossref_primary_10_1021_acs_molpharmaceut_4c01341 crossref_primary_10_3390_vaccines12091043 crossref_primary_10_1073_pnas_0912914107 crossref_primary_10_1126_science_1241144 crossref_primary_10_1016_j_chom_2014_08_006 crossref_primary_10_1096_fj_08_113142 crossref_primary_10_1016_j_ijpharm_2015_02_021 crossref_primary_10_1002_jmr_928 crossref_primary_10_1097_COH_0000000000000364 crossref_primary_10_1128_JVI_05680_11 crossref_primary_10_3390_v6125047 crossref_primary_10_1128_JVI_00685_09 crossref_primary_10_1097_COH_0b013e32832e6184 crossref_primary_10_1371_journal_pone_0007215 crossref_primary_10_1016_j_cell_2016_02_022 crossref_primary_10_1016_j_ebiom_2015_06_016 crossref_primary_10_1182_blood_2012_03_418913 crossref_primary_10_1128_JVI_00927_07 crossref_primary_10_1016_j_bbamem_2014_07_007 crossref_primary_10_1016_j_virol_2007_11_009 crossref_primary_10_1002_jmr_1116 crossref_primary_10_1016_j_cell_2024_04_033 crossref_primary_10_1128_JVI_00426_12 crossref_primary_10_1038_srep40800 crossref_primary_10_1371_journal_ppat_1003202 crossref_primary_10_7554_eLife_90139_3 crossref_primary_10_1016_j_immuni_2015_12_001 crossref_primary_10_1089_aid_2011_0226 crossref_primary_10_4049_jimmunol_1601484 crossref_primary_10_1016_j_virol_2009_05_015 crossref_primary_10_1073_pnas_1301456110 crossref_primary_10_1128_JVI_00412_15 crossref_primary_10_1371_journal_pone_0037157 crossref_primary_10_1007_s13238_018_0534_7 crossref_primary_10_1128_jvi_01594_23 crossref_primary_10_1084_jem_20121977 crossref_primary_10_1016_j_bbrc_2008_08_105 crossref_primary_10_1084_jem_20091281 crossref_primary_10_4049_jimmunol_1101080 crossref_primary_10_1038_nsmb_2154 crossref_primary_10_1007_s12250_015_3664_6 crossref_primary_10_1016_j_jaci_2008_03_036 crossref_primary_10_1128_JVI_01558_09 crossref_primary_10_1371_journal_ppat_1000203 crossref_primary_10_1371_journal_pcbi_1003431 crossref_primary_10_1016_j_jneuroim_2011_08_002 crossref_primary_10_1016_j_virol_2020_06_016 crossref_primary_10_1021_acsami_4c13353 crossref_primary_10_1128_JVI_01739_14 crossref_primary_10_1517_14712598_2012_688020 crossref_primary_10_1371_journal_pone_0027824 crossref_primary_10_1128_cmr_00152_22 crossref_primary_10_3389_fimmu_2017_01154 crossref_primary_10_1128_JVI_06349_11 crossref_primary_10_1186_1758_2652_12_2 crossref_primary_10_1016_j_virol_2017_04_008 crossref_primary_10_1186_s12979_024_00415_6 crossref_primary_10_1038_mi_2009_89 crossref_primary_10_1128_JVI_05086_11 crossref_primary_10_1016_j_immuni_2012_11_011 crossref_primary_10_1016_j_vaccine_2011_11_048 crossref_primary_10_1073_pnas_0908713106 crossref_primary_10_1093_protein_gzaa025 crossref_primary_10_1016_j_jmb_2010_01_064 crossref_primary_10_1111_imr_12513 crossref_primary_10_1073_pnas_1012051108 crossref_primary_10_1016_j_vaccine_2011_06_085 crossref_primary_10_1116_1_3432480 crossref_primary_10_1128_AAC_02097_15 crossref_primary_10_1016_j_immuni_2007_12_005 crossref_primary_10_1111_imr_12075 crossref_primary_10_1128_MMBR_00020_07 crossref_primary_10_1128_IAI_00529_07 crossref_primary_10_4049_jimmunol_1101633 crossref_primary_10_1002_cbic_200800609 crossref_primary_10_4049_jimmunol_1302511 crossref_primary_10_1371_journal_ppat_1005042 crossref_primary_10_1371_journal_ppat_1006098 crossref_primary_10_1128_JVI_00156_14 crossref_primary_10_4049_jimmunol_1300971
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8
DOI	10.4049/jimmunol.178.7.4424
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Biology
EISSN	1365-2567
EndPage	4435
ExternalDocumentID	17372000
Genre	Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NIAID NIH HHS grantid: U19 AI067854 – fundername: NIAID NIH HHS grantid: P30 AI051445 – fundername: NIAID NIH HHS grantid: P01 AI 52816 – fundername: NIAID NIH HHS grantid: AI 51445 – fundername: NIAID NIH HHS grantid: P01 AI052816 – fundername: NIAID NIH HHS grantid: AI 06785-01
GroupedDBID	--- -~X .55 0R~ 18M 2WC 34G 39C 3O- 53G 5GY 5RE 5VS 5WD 79B 85S AARDX ABCQX ABDFA ABEFU ABEJV ABGNP ABJNI ABOCM ABPPZ ACGFO ACGFS ACIWK ACNCT ACPRK ADBBV ADIPN ADNWM ADXHL AENEX AETEA AFFNX AFHIN AFOSN AFRAH AGORE AHMMS AHWXS AIZAD ALMA_UNASSIGNED_HOLDINGS ARBBW BAWUL BCRHZ BTFSW CGR CUY CVF D0L DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 H13 IH2 J5H K-O KQ8 L7B MVM NEJ NPM OCZFY OK1 OWPYF P0W P2P PQQKQ R.V RHI ROX RZQ SJN TR2 TWZ W8F WH7 WOQ X7M XJT XSW XTH YHG ZE2 ZGI .3N .GA .Y3 05W 10A 1OC 29I 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5HH 5LA 66C 702 7PT 7T5 7U9 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 A8Z AAESR AAEVG AAFWJ AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABPVW ABQWH ABXGK ACAHQ ACCZN ACGOF ACMXC ACPOU ACUHS ACXBN ACXQS ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEFGJ AEGXH AEIGN AEIMD AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFWVQ AFZJQ AGXDD AGYGG AHBTC AIACR AIAGR AIDQK AIDYY AITYG AIURR ALAGY ALUQN ALVPJ AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM EAD EAP EAS EBB EBC EBD EBX EMB EMK EMOBN EPT ESTFP ESX EX3 F00 F01 F04 FD6 FIJ FUBAC G-S G.N GODZA H.X H94 HGLYW HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OBC OBS OIG OVD P2W P2X P2Z P4B P4D Q.N Q11 QB0 Q~Q R.K ROL RPM RX1 SUPJJ SV3 TEORI TUS UB1 UPT V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WVDHM WXI WXSBR XG1 YF5 YFH YOC YUY ZZTAW ~IA ~KM ~WT 7X8 ABXVV KOP
ID	FETCH-LOGICAL-c532t-536bbf30d0dbf788466429de722a3d809b5e22e324a3723d68f2fafe2bcb243b3
ISICitedReferencesCount	228
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000245197300050&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0022-1767
IngestDate	Sun Nov 09 12:47:19 EST 2025 Fri Sep 05 13:46:22 EDT 2025 Fri May 30 10:49:37 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	7
Language	English
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c532t-536bbf30d0dbf788466429de722a3d809b5e22e324a3723d68f2fafe2bcb243b3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://www.jimmunol.org/content/jimmunol/178/7/4424.full.pdf
PMID	17372000
PQID	19604762
PQPubID	23462
PageCount	12
ParticipantIDs	proquest_miscellaneous_70303077 proquest_miscellaneous_19604762 pubmed_primary_17372000
PublicationCentury	2000
PublicationDate	2007-Apr-01 20070401
PublicationDateYYYYMMDD	2007-04-01
PublicationDate_xml	– month: 04 year: 2007 text: 2007-Apr-01 day: 01
PublicationDecade	2000
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Journal of Immunology
PublicationTitleAlternate	J Immunol
PublicationYear	2007
SSID	ssj0006024 ssj0013055
Score	2.3592982
Snippet	Two neutralizing human mAbs, 2F5 and 4E10, that react with the HIV-1 envelope gp41 membrane proximal region are also polyspecific autoantibodies that bind to...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	4424
SubjectTerms	Amino Acid Sequence Animals Antibodies, Monoclonal - chemistry Antibodies, Monoclonal - immunology Antibody Specificity Antiphospholipid Syndrome - immunology Autoantibodies - immunology Cardiolipins - immunology HIV Antibodies - immunology HIV Envelope Protein gp41 - immunology HIV-1 - immunology Human immunodeficiency virus 1 Humans Lipids - immunology Liposomes - chemistry Mice Molecular Sequence Data
Title	The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes
URI	https://www.ncbi.nlm.nih.gov/pubmed/17372000 https://www.proquest.com/docview/19604762 https://www.proquest.com/docview/70303077
Volume	178
WOSCitedRecordID	wos000245197300050&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1365-2567 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0013055 issn: 0022-1767 databaseCode: WIN dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1365-2567 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013055 issn: 0022-1767 databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELa25SEuCJbX8lh8QFyqdBMnqZNjQS1baVMq6EJvURI7UkQ3Kd121fIr-UnMOE4TCivgwCWqrHjsaL6OZ8bzIOSV6zMJWrZppBEThmNzbkQJCEOOVa0tvNlhsWo2wcdjbzbzJwetdpULczXnee5tNv7iv7IaxoDZmDr7D-zeEYUB-A1MhyewHZ5_zfgPOmawn6-yuBBbDHPbYlIlBgah3o3ucmxbjcmJmNqgOkhkeedNVma5wFww0CMx34IYXCtvyDflQAGCxunok2F1BrkKN5L6HgCEQ5HMlV9Rrwo2eIcNXbWWM7BMVHPfzbdJoWpDwGKO1QnkBZjroOhOlsUmu8AixxXZwQKEzUKHOP6qPo8wseWnO4G-BvfHYJ1nu5jjIOkL7U8KVN662HkgiqWWuXVcP154fdlPJ6icIrwRS1MnKVi87PTRlaVsVwF9rh6rhD_3GijnDVHuOGVyt1YLHKcsq7J_5DhgYuGRk5Vf3QWCXd6tJzcLfI_fh8Pzs7NwOphNXy--Gtj7DGMEdCOYFrnBuOtjYOLn0XinT_RMTOCpLsZM160K4OP3lYW0cBMnv9nC9WaTUp-m98hdzTjaL_F6nxzI_JDcKjuhbg_J7UDHeDwg3wHAFAFMi5RWAKZ7AKYAKqoATGsA0yynGsA4VwOYNgFMawDTCmlUAZjWAKY1gCkAWK2FAKargjYBTB2LVgCmFYBrshWAH5Lz4WD69tTQfUeMxLXZynDtXhyntilMEafc87ADA_OF5IxFtvBMP3YlYxJMkcjmzBY9L2VplEoWJzFz7Nh-RNp5kcsnhLLY9qW0Iyk8y2GWiBNTxq7wgUyCpsoReVkxKAS5jpd1sOVifRlaWDUJNJXr38CzGk5ofkQel5wNF2WBmtBSvadM8-kfqT8jd-q_z3PSXi3X8gW5mVytssvlMWnxmQfP8SQ4Vpj8AZ6K3PY
linkProvider	Wiley-Blackwell
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Role+of+Antibody+Polyspecificity+and+Lipid+Reactivity+in+Binding+of+Broadly+Neutralizing+Anti-HIV-1+Envelope+Human+Monoclonal+Antibodies+2F5+and+4E10+to+Glycoprotein+41+Membrane+Proximal+Envelope+Epitopes&rft.jtitle=Journal+of+Immunology&rft.au=Alam%2C+SMunir&rft.au=McAdams%2C+Mildred&rft.au=Boren%2C+David&rft.au=Rak%2C+Michael&rft.date=2007-04-01&rft.issn=0022-1767&rft.eissn=1365-2567&rft.volume=178&rft.issue=7&rft.spage=4424&rft.epage=4435&rft_id=info:doi/10.4049%2Fjimmunol.178.7.4424&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1767&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1767&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1767&client=summon